Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Non-Small-Cell Lung Cancer (NSCLC)

Sugemalimab with Chemo Demonstrates Improvement in NSCLC Survival Rates

Posted on January 24, 2022
Post Views: 243

Non-Small-Cell Lung Cancer (NSCLC)In the year 2020, an estimate of 2.2 million people has been diagnosed with lung cancer. It is the second most commonly diagnosed cancer and is among leading cause of cancer deaths. NSCLC is the most common type of lung cancer, accounting for about 84% of all lung cancer diagnoses. The lung cancer drug, sugemalimab, has shown positive results following a phase 3 trial.

The GEMSTONE-302 study has evaluated the efficacy of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-time treatment for stage 4 NSCLC versus using chemotherapy alone for such patients. The results from two phase III trials have shown that sugemalimab has significantly prolonged progression-free survival in NSCLC patients. In this trial, they have found that use of sugemalimab after chemotherapy in patients with locally advanced, unresectable stage III NSCLC resulted in significantly longer progression-free survival.  The results from the study were published in The Lancet Oncology.

The analysis from Gemstone-32 has shown that at a median follow-up of 17.8 months, sugemalimab with chemotherapy improved progression-free survival in comparison with placebo with chemotherapy in patients with previously untreated squamous and non-squamous metastatic non-small cell lung cancer, irrespective of PD-L1 expression levels.

“We are highly encouraged to see that sugemalimab in combination with chemotherapy demonstrates significant clinical benefit, including improvement in both PFS and OS, when compared to placebo plus chemotherapy across a broad spectrum of patients with stage IV NSCLC in this phase 3 study,” Vince Miller, MD, physician-in-chief at EQRx, stated in a press release. “Price remains a barrier to accessing innovative therapies for many people with lung cancer around the world, despite the availability of multiple anti-PD-(L)1 therapies,” he added.

The detailed results of the GEMSTONE-302 study will be presented at a future medical congress.

The information shared in this blog is for educational purposes only. Please consult your medical practitioner for any health issues.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d